Ovensa Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Out of Business

  • Employees
  • 2

Employees

  • Latest Deal Type
  • Liquidation

Ovensa General Information

Description

Developer of novel drug molecules designed to treat cancer and neurodegenerative diseases. The company leverages its proprietary platforms to overcome drug delivery challenges such as crossing the mucosal and blood-brain barriers, cell targeting, payload internalization, and precision and combination medicines to silence overexpression in the tumor microenvironment, enabling pharmaceutical companies to enhance the stability and delivery of their ribonucleic acid (RNA) therapeutics, antibodies, or peptides for the vaccine.

Contact Information

Website
www.ovensa.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 199 Bay Street
  • Suite 4000
  • Toronto, Ontario M5L 1A9
  • Canada
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 199 Bay Street
  • Suite 4000
  • Toronto, Ontario M5L 1A9
  • Canada

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ovensa Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Bankruptcy: Liquidation 01-Dec-2024 Completed Bankruptcy: Liquidation
4. Later Stage VC (Series A) 24-Dec-2020 Completed Pre-Clinical Trials
3. Seed Round 19-Sep-2017 Completed Pre-Clinical Trials
2. Seed Round 21-Jun-2016 $530K $530K Completed Startup
1. Grant 01-Apr-2015 $23.8K Completed Startup
To view Ovensa’s complete valuation and funding history, request access »

Ovensa Patents

  • 2

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • Pending

  • Expiring in next 12 mo

Ovensa Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2024259525-A1 Nanoparticles comprising n,n,n-trimethyl chitosan coated with peptide agonists of kinin b1 or b2 and/or peptide antagonists of kinin b1 for transvascular drug delivery across the blood-brain barrier Inactive 19-Jun-2023
WO-2019169478-A1 Treatment of protein aggregation diseases using n,n,n-trimethylchitosan Inactive 05-Mar-2018

Ovensa Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ready to get started?

Request a free trial

Ovensa FAQs

  • When was Ovensa founded?

    Ovensa was founded in 2012.

  • Where is Ovensa headquartered?

    Ovensa is headquartered in Toronto, Canada.

  • What is the size of Ovensa?

    Ovensa has 2 total employees.

  • What industry is Ovensa in?

    Ovensa’s primary industry is Drug Discovery.

  • Is Ovensa a private or public company?

    Ovensa is a Private company.

  • What is Ovensa’s current revenue?

    The current revenue for Ovensa is .

  • How much funding has Ovensa raised over time?

    Ovensa has raised $16.9M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process